scopolamine HBr
Phase 3Small molecule
scopolamine HBr is one of 9 small molecule programs targeting Motion Sickness. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Motion Sickness
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Phenergan
BBassett Healthcare
Approved
Transderm Scop
BBaxter Healthcare Corporation
Phase 3
Nereus
VVanda Pharmaceuticals
Phase 2
Other
AstraZenecaPhase 2
scopolamine HBr
RRepurposed Therapeutics, Inc.
Phase 3
Transderm Scop
RRepurposed Therapeutics, Inc.
Phase 3
Rizafilm
OOrganon and Co
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for scopolamine HBr. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRepurposed Therapeutics, Inc.